Alps Advisors Inc. acquired a new stake in MediciNova, Inc. (NASDAQ:MNOV) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 40,004 shares of the biopharmaceutical company’s stock, valued at approximately $259,000.

Other institutional investors have also made changes to their positions in the company. Voya Investment Management LLC boosted its stake in shares of MediciNova by 22.9% in the 2nd quarter. Voya Investment Management LLC now owns 19,341 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 3,603 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of MediciNova in the 3rd quarter valued at $118,000. Wells Fargo & Company MN boosted its stake in shares of MediciNova by 63.3% in the 3rd quarter. Wells Fargo & Company MN now owns 32,575 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 12,624 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of MediciNova by 75.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 47,656 shares of the biopharmaceutical company’s stock valued at $251,000 after purchasing an additional 20,567 shares in the last quarter. Finally, Teachers Advisors LLC boosted its stake in shares of MediciNova by 7.2% in the 2nd quarter. Teachers Advisors LLC now owns 54,649 shares of the biopharmaceutical company’s stock valued at $287,000 after purchasing an additional 3,673 shares in the last quarter. 22.00% of the stock is owned by institutional investors.

MNOV has been the subject of several analyst reports. BidaskClub cut shares of MediciNova from a “buy” rating to a “hold” rating in a research report on Saturday, January 20th. ValuEngine raised shares of MediciNova from a “sell” rating to a “hold” rating in a research report on Wednesday, February 7th.

Shares of MediciNova, Inc. (NASDAQ MNOV) opened at $9.87 on Thursday. The firm has a market cap of $374.06, a price-to-earnings ratio of -30.84 and a beta of 0.38. MediciNova, Inc. has a 12-month low of $4.40 and a 12-month high of $11.45.

WARNING: “Alps Advisors Inc. Invests $259,000 in MediciNova, Inc. (MNOV)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2018/02/15/alps-advisors-inc-invests-259000-in-medicinova-inc-mnov.html.

MediciNova Company Profile

Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).

Want to see what other hedge funds are holding MNOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MediciNova, Inc. (NASDAQ:MNOV).

Institutional Ownership by Quarter for MediciNova (NASDAQ:MNOV)

Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.